...−) progressive metastatic breast cancer (MBC). The SOLAR-1 trial demonstrated the efficacy of this oral agent and showed that, while alpelisib improves outcomes compared to placebo, it is also associated with clinically relevant adverse events (AEs). There is a pressing need for improved knowledge...

...Yaning He; Qi Chen; Fangyuan Zhu; Chaojun Liu; Yingbo Shao; Hui Liu Introduction: Radiotherapy (RT) plays an indispensable role in postoperative breast cancer treatment. This study aimed to assess the feasibility of preoperative RT for stage III breast cancer by comparing preoperative RT...

... subtype of breast cancer. However, this molecular type requires more effective treatment regimens in the neoadjuvant therapy stage. Methods: This study enrolled breast cancer patients who were treated at Harbin Medical University Cancer Hospital with neoadjuvant treatment between October 2011 and May 2019...

...Langfeier Liu; Nicholas Lewis; Weihong Sun; Junmin Whiting; Susan Hoover; Ricardo L.B. Costa Introduction: T1a/b, node-negative (node − ), triple-negative breast cancers (TNBCs) are underrepresented in randomized drug-approving clinical trials. Given their low incidence, the clinicopathological...

...Yu Yang; Chang Liu; Zhong-Ling Zhuo; Fei Xie; Ke Wang; Shu Wang; Xiao-Tao Zhao Introduction: BRCA1/2 germline mutations are the most well-known genetic determinants for breast cancer. However, the distribution of germline mutations in non-BRCA1/2 cancer susceptibility genes in Chinese breast cancer...

...Izzet Dogan; Inci Kizildag; Selnur Özkurt; Kamuran Ibis; Sezai Vatansever; Pinar Saip; Adnan Aydiner Introduction: Patients with HER2-positive metastatic breast cancer are at risk for developing brain metastases. Different anti-HER2 treatments can be used in the management of the disease...

... with hormone receptor (HR)-positive and human epidermal growth factor receptor 2 (HER2)-negative breast cancer after NAC. Methods: We evaluated 417 patients who were diagnosed with invasive breast cancer and treated with NAC followed by curative surgery between January 2007 and December 2020 and analyzed...

...Vivien Nguyen; Juliana Chen; Reginald Lord; Veronica Preda Introduction: Weight gain during chemotherapy for breast cancer is a well-documented adverse effect. The purpose of this study was to investigate how multidisciplinary weight management involving endocrinology, dietitian, and exercise...

... for patients with human epidermal growth factor receptor 2 (HER2)-positive early breast cancer in the adjuvant setting, but not in the neoadjuvant chemotherapy (NAC) setting. We investigated whether anthracycline can be omitted in HER2-positive early breast cancer patients receiving neoadjuvant taxane plus...

... reaction of bisphosphonates and denosumab, and Actinomyces spp. as well. In this study, we evaluated the abundance of Actinomyces spp. in breast cancer patients undergoing chemotherapy compared to healthy controls. Methods: Oropharyngeal samples were collected from treatment-naive early-stage breast cancer...

...Kei Yamaguchi; Ryoichi Matsunuma; Ryosuke Hayami; Michiko Tsuneizumi Introduction: Not only the 21-gene recurrence score (RS) assay but also online prognostic tools and immunohistochemical prognostic models predict chemotherapy benefits for women with early breast cancer (BC). Multigene assays...

...Orly Yariv; Raz Mutai; Ofer Rotem; Daliah Tsoref; Yasmin Korzets; Assaf Moore; Tzippy Shochat; Rinat Yerushalmi; Hadar Goldvaser Introduction: The impact of exogenous estrogen exposure on breast cancer characteristics and outcomes is not well described. We aimed to investigate the effect of prior...

... with early-stage, hormone-positive (HR+) breast cancer (BC), with higher scores predicting greater risk of recurrence and benefit from chemotherapy. Patients with ODx RS >25 typically recieve adjuvant chemotherapy; however, data regarding efficacy of chemotherapy for reducing recurrence in this population...

... dissection can be decided. Objectives: The aim of this study was to validate three existing nomograms predicting 4 or more axillary lymph node metastases. Method: The risk for ≥4 lymph node metastases was calculated for n = 529 eligible breast cancer patients using the nomograms of Chagpar et al. [Ann Surg...

...Brittney S. Zimmerman; Danielle Seidman; Krystal P. Cascetta; Meng Ru; Erin Moshier; Amy Tiersten Introduction: The aim of this study was to assess for clinicopathologic and socioeconomic features that predict improved survival for patients with advanced breast cancer with synchronous brain...

...Claudia Borreani; Sara Alfieri; Gabriele Infante; Rosalba Miceli; Paola Mariani; Marco Bosisio; Claudio Vernieri; Giulia V. Bianchi; Giuseppe Capri Background: Aromatase inhibitors (AIs) as adjuvant therapy after breast cancer (BC) surgery have demonstrated to reduce the risk of disease recurrence...

... detection of distant breast cancer recurrence using FDG-PET/CT. Methods: We retrospectively analyzed 561 consecutive patients who underwent surgery for invasive primary breast cancer and had increased tumor markers (CA 15-3 and CEA) after completion of locoregional therapy. FDG-PET/CT data were reviewed...

...Sreeja Dattachoudhury; Renu Sharma; Atul Kumar; Bithiah Grace Jaganathan Introduction: Metastatic breast cancer has poor prognosis due to limited therapeutic options. Protein kinase dysregulations have a major role in breast cancer progression and metastasis. In this study, we investigated the anti...

...Serena Tharakan; Brittney Zimmerman; Meng Ru; Julia Blanter; Krystal Cascetta; Amy Tiersten Background: The Oncotype DX® (ODX) is a genomic assay that provides clinicians with a prediction of benefit of chemotherapy in node-negative, tamoxifen-treated breast cancer. However, the relationship...

...Julia Blanter; Brittney Zimmerman; Serena Tharakan; Meng Ru; Krystal Cascetta; Amy Tiersten Background: The Oncotype DX Breast Cancer Assay is a 21-gene assay used to predict the likelihood of distant recurrence and the benefit of chemotherapy in patients with node-negative, tamoxifen-treated...